Paper39343752
Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives.
Kim HJ and 1 other. Ann Dermatol, 2024. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives. Papers, record 39343752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39343752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 AR076766 | NIAMS NIH HHS | United States | R01AR076766 | PubMed |
Source NIH RePORTER
References81
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25702838 | β2-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system. | J Allergy Clin Immunol | 2015 | https://conductscience.org/library/papers/25702838 | PubMed |
| 2 | 37331616 | Validation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and Other Efficacy Outcomes as Measures of Skin Disease in Dermatomyositis in the Lenabasum Phase 3 Trial. | J Invest Dermatol | 2023 | https://conductscience.org/library/papers/37331616 | PubMed |
| 3 | 28652111 | Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro. | J Invest Dermatol | 2017 | https://conductscience.org/library/papers/28652111 | PubMed |
| 4 | 23190767 | The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. | Clin Exp Rheumatol | 2013 | https://conductscience.org/library/papers/23190767 | PubMed |
| 5 | 12529736 | Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. | Thromb Haemost | 2002 | https://conductscience.org/library/papers/12529736 | PubMed |
| 6 | 21482889 | Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. | Arch Dermatol | 2011 | https://conductscience.org/library/papers/21482889 | PubMed |
| 7 | 30657093 | Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series. | Adv Rheumatol | 2018 | https://conductscience.org/library/papers/30657093 | PubMed |
| 8 | 33675790 | Myeloid Dendritic Cells Are Major Producers of IFN-β in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness. | J Invest Dermatol | 2021 | https://conductscience.org/library/papers/33675790 | PubMed |
| 9 | 24506658 | Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. | Mod Rheumatol | 2014 | https://conductscience.org/library/papers/24506658 | PubMed |
| 10 | 29741608 | JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. | Brain | 2018 | https://conductscience.org/library/papers/29741608 | PubMed |
| 11 | 30508240 | Dermatomyositis: a slow path towards targeted therapies or will conventional therapies prevail? | Br J Dermatol | 2018 | https://conductscience.org/library/papers/30508240 | PubMed |
| 12 | 36578492 | Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis. | Front Immunol | 2022 | https://conductscience.org/library/papers/36578492 | PubMed |
| 13 | 31279813 | Dermatomyositis: Diagnosis and treatment. | J Am Acad Dermatol | 2020 | https://conductscience.org/library/papers/31279813 | PubMed |
| 14 | 36622138 | Current concepts and advances in dermatomyositis: a dermatological perspective. | Clin Exp Rheumatol | 2023 | https://conductscience.org/library/papers/36622138 | PubMed |
| 15 | 35490744 | Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial. | J Invest Dermatol | 2022 | https://conductscience.org/library/papers/35490744 | PubMed |
| 16 | 23680200 | Methotrexate for the treatment of cutaneous dermatomyositis. | J Am Acad Dermatol | 2013 | https://conductscience.org/library/papers/23680200 | PubMed |
| 17 | 21981743 | Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. | Clin Exp Dermatol | 2012 | https://conductscience.org/library/papers/21981743 | PubMed |
| 18 | 24856183 | Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity. | Bioorg Med Chem | 2014 | https://conductscience.org/library/papers/24856183 | PubMed |
| 19 | 17576943 | A pilot trial of rituximab in the treatment of patients with dermatomyositis. | Arch Dermatol | 2007 | https://conductscience.org/library/papers/17576943 | PubMed |
| 20 | 32057402 | The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review. | Semin Arthritis Rheum | 2020 | https://conductscience.org/library/papers/32057402 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41910912 | Association of malnutrition with in-hospital outcomes among patients hospitalized with dermatomyositis or polymyositis. | Clin Rheumatol | 2026 | https://conductscience.org/library/papers/41910912 | PubMed |
| 41768519 | Dermatomyositis: Prevalence, Clinical Spectrum, Diagnostic Approach, and Management Strategies. | Arch Intern Med Res | 2026 | https://conductscience.org/library/papers/41768519 | PubMed |
| 41545853 | Dermatomyositis and Polymyositis: Are Both Ends of a Same Spectrum? | J Cosmet Dermatol | 2026 | https://conductscience.org/library/papers/41545853 | PubMed |
| 41441445 | An Update on Dermatomyositis and Related Inflammatory Myopathies: Cutaneous Clues, Skeletal Muscle Involvement, and Advances in Pathogenesis and Treatment. | Muscles | 2025 | https://conductscience.org/library/papers/41441445 | PubMed |
| 40770118 | Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment. | Semin Immunopathol | 2025 | https://conductscience.org/library/papers/40770118 | PubMed |
| 40227497 | The Importance and Challenges of Early Diagnosis of Paraneoplastic Skin Syndromes in Cancer Detection-A Review. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40227497 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39343752
GET https://conductscience.org/api/papers/v1/39343752/references?page=2